BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Core Insights - BioNTech and Bristol Myers Squibb have developed a next-generation cancer immunotherapy that has shown promising results in reducing tumor size during a mid-stage trial for small cell lung cancer [1] Company Summary - The mid-stage trial focused on small cell lung cancer, a type of cancer that has begun to spread, indicating the urgency and significance of the treatment being tested [1] Industry Summary - The results from this trial could have implications for the broader field of cancer immunotherapy, particularly in the treatment of aggressive cancers like small cell lung cancer [1]